Table 5.
Survival analyses according to treatment response
| DC bead |
P-value | ||
|---|---|---|---|
| PR+SD | PD+not applicable | ||
| ITT | 18 | 12 | |
| Time to progression (days) | 207 (57–207) | 35 (22–42) | <0.0001* |
| Progression in HCC | 18 | 8 | |
| Yes | 3 (16.67) | 8 (100.00) | 0.0001† |
| No | 15 (83.33) | 0 (0.00) | |
| Overall survival rate (days) | 224 (131–389) | 176 (80–260) | 0.0487* |
| Survival rate | 18 | 12 | |
| Yes | 12 (66.67) | 9 (75.00) | 0.7036† |
| No | 6 (33.33) | 3 (25.00) | |
| Progression-free survival | 18 | 12 | |
| Yes | 13 (72.22) | 10 (83.33) | 0.6693† |
| No | 5 (27.78) | 2 (16.67) | |
| Time to progression free survival (days) | 207 (102–367) | 41 (28–248) | 0.0037 |
Values are presented as median survival time (95% confidence interval) or number (%).
PR, partial response; SD, stable disease; PD, progressive disease; ITT, intention-to-treat; HCC, hepatocellular carcinoma.
*
P-value: Log rank test;
†
P-value: Fisher’s exact test.